Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05110937 · ClinicalTrials.gov registry record
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
A clinical trial of Sepsis and Trauma Injury, sponsored by University of Florida.
- Recruiting
- Registry status
- 450
- Enrollment target
- 1
- Study location
NCT05110937 is a study of Sepsis and Trauma Injury that is actively recruiting participants, run by University of Florida. The registered enrollment target is 450 participants, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05110937, a study of Sepsis and Trauma Injury, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
Conditions Studied
Interventions
- OTHER Blood sampling
Study Locations (1)
Florida
- UF Health at Shands hospital - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2027-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05110937
The ClinicalTrials.gov registry entry for NCT05110937 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,560-participant average among 90 other Sepsis trials with a reported enrollment target (93% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Blood sampling is the first listed.
NCT05110937 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05110937 about?
NCT05110937 is a clinical study titled "Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis". Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms tha...
What is the current status of trial NCT05110937?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2022-01-04. Estimated completion is 2027-04.
What conditions does trial NCT05110937 study?
This clinical trial studies the following conditions: Sepsis, Trauma Injury.
What interventions are being tested in trial NCT05110937?
The interventions under investigation include: Blood sampling (OTHER).
Who is sponsoring clinical trial NCT05110937?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05110937 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.